Baseline Characteristics of the Included 48 210 Employees of Cleveland Clinic in Ohio, and Features of Those who Did and Did not Receive the 2023–2024 Formulation COVID-19 Vaccine by the end of the Study
| Characteristics . | All Subjects (n = 48 210) . | Vaccinateda by the End of the Study (n = 7978) . | Not Vaccinateda by the End of the Study (n = 40 232) . | P . |
|---|---|---|---|---|
| Age in y, mean (SD) | 42.0 (13.4) | 47.6 (13.9) | 40.9 (13.0) | <.001 |
| Sex | <.001 | |||
| Female | 35 959 (74.6) | 5421 (67.9) | 30 538 (75.9) | |
| Male | 12 251 (25.4) | 2557 (32.1) | 9694 (24.1) | |
| Location | <.001 | |||
| Cleveland Clinic Main | 19 935 (41.4) | 4476 (56.1) | 15 459 (38.4) | |
| Cleveland area regional hospitals | 12 289 (25.5) | 1450 (18.2) | 10 839 (26.9) | |
| Ambulatory centers | 8922 (18.5) | 1198 (15.0) | 7724 (19.2) | |
| Cleveland Clinic Akron | 4075 (8.5) | 348 (4.4) | 3727 (9.3) | |
| Administrative centers | 1779 (3.7) | 377 (4.7) | 1402 (3.5) | |
| Cleveland Clinic Medina | 1210 (2.5) | 129 (1.6) | 1081 (2.7) | |
| Hire cohort | <.001 | |||
| Prepandemic | 28 030 (58.1) | 5404 (67.7) | 22 626 (56.2) | |
| Pandemic | 20 180 (41.9) | 2574 (32.3) | 17 606 (43.8) | |
| Pandemic phase during which most recent infection occurred | <.001 | |||
| Not previously known to be infected | 26 494 (55.0) | 4526 (56.7) | 21 968 (54.6) | |
| Pre-Omicron | 5055 (10.5) | 472 (5.9) | 4583 (11.4) | |
| Omicron pre-XBB | 13 499 (28.0) | 2360 (29.6) | 11 139 (27.7) | |
| Omicron XBB or later | 3162 (6.6) | 620 (7.8) | 2542 (6.3) | |
| Days since most recent infection, mean (SD) | 544 (284) | 478 (260) | 557 (286) | <.001 |
| Prior vaccination history | <.001 | |||
| Monovalent and bivalent vaccines | 12 264 (25.4) | 5876 (73.7) | 6388 (15.9) | |
| Bivalent vaccine only | 379 (<1) | 111 (1.4) | 268 (<1) | |
| Monovalent vaccine only | 28 192 (58.5) | 1722 (21.6) | 26 470 (65.8) | |
| Non-mRNA vaccine only | 913 (1.9) | 23 (<1) | 890 (2.2) | |
| No vaccine | 6462 (13.4) | 246 (3.1) | 6216 (15.5) | |
| Number of prior vaccine doses | <.001 | |||
| 0 | 6462 (13.4) | 246 (3.1) | 6216 (15.5) | |
| 1 | 1904 (3.9) | 134 (1.7) | 1770 (4.4) | |
| 2 | 13 381 (27.8) | 303 (3.8) | 13 078 (32.5) | |
| 3 | 14 106 (29.3) | 1287 (16.1) | 12 819 (31.9) | |
| >3 | 12 357 (25.6) | 6008 (75.3) | 6349 (15.8) | |
| Days since most recent vaccine, mean (SD) | 597 (232) | 377 (197) | 648 (209) | <.001 |
| Days since proximate SARS-CoV-2 exposureb, mean (SD) | 513 (239) | 339 (188) | 551 (232) | <.001 |
| Characteristics . | All Subjects (n = 48 210) . | Vaccinateda by the End of the Study (n = 7978) . | Not Vaccinateda by the End of the Study (n = 40 232) . | P . |
|---|---|---|---|---|
| Age in y, mean (SD) | 42.0 (13.4) | 47.6 (13.9) | 40.9 (13.0) | <.001 |
| Sex | <.001 | |||
| Female | 35 959 (74.6) | 5421 (67.9) | 30 538 (75.9) | |
| Male | 12 251 (25.4) | 2557 (32.1) | 9694 (24.1) | |
| Location | <.001 | |||
| Cleveland Clinic Main | 19 935 (41.4) | 4476 (56.1) | 15 459 (38.4) | |
| Cleveland area regional hospitals | 12 289 (25.5) | 1450 (18.2) | 10 839 (26.9) | |
| Ambulatory centers | 8922 (18.5) | 1198 (15.0) | 7724 (19.2) | |
| Cleveland Clinic Akron | 4075 (8.5) | 348 (4.4) | 3727 (9.3) | |
| Administrative centers | 1779 (3.7) | 377 (4.7) | 1402 (3.5) | |
| Cleveland Clinic Medina | 1210 (2.5) | 129 (1.6) | 1081 (2.7) | |
| Hire cohort | <.001 | |||
| Prepandemic | 28 030 (58.1) | 5404 (67.7) | 22 626 (56.2) | |
| Pandemic | 20 180 (41.9) | 2574 (32.3) | 17 606 (43.8) | |
| Pandemic phase during which most recent infection occurred | <.001 | |||
| Not previously known to be infected | 26 494 (55.0) | 4526 (56.7) | 21 968 (54.6) | |
| Pre-Omicron | 5055 (10.5) | 472 (5.9) | 4583 (11.4) | |
| Omicron pre-XBB | 13 499 (28.0) | 2360 (29.6) | 11 139 (27.7) | |
| Omicron XBB or later | 3162 (6.6) | 620 (7.8) | 2542 (6.3) | |
| Days since most recent infection, mean (SD) | 544 (284) | 478 (260) | 557 (286) | <.001 |
| Prior vaccination history | <.001 | |||
| Monovalent and bivalent vaccines | 12 264 (25.4) | 5876 (73.7) | 6388 (15.9) | |
| Bivalent vaccine only | 379 (<1) | 111 (1.4) | 268 (<1) | |
| Monovalent vaccine only | 28 192 (58.5) | 1722 (21.6) | 26 470 (65.8) | |
| Non-mRNA vaccine only | 913 (1.9) | 23 (<1) | 890 (2.2) | |
| No vaccine | 6462 (13.4) | 246 (3.1) | 6216 (15.5) | |
| Number of prior vaccine doses | <.001 | |||
| 0 | 6462 (13.4) | 246 (3.1) | 6216 (15.5) | |
| 1 | 1904 (3.9) | 134 (1.7) | 1770 (4.4) | |
| 2 | 13 381 (27.8) | 303 (3.8) | 13 078 (32.5) | |
| 3 | 14 106 (29.3) | 1287 (16.1) | 12 819 (31.9) | |
| >3 | 12 357 (25.6) | 6008 (75.3) | 6349 (15.8) | |
| Days since most recent vaccine, mean (SD) | 597 (232) | 377 (197) | 648 (209) | <.001 |
| Days since proximate SARS-CoV-2 exposureb, mean (SD) | 513 (239) | 339 (188) | 551 (232) | <.001 |
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: COVID-19, coronavirus disease 2019; mRNA, messenger RNA; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.
aWith the 2023–2024 formulation vaccine.
bBy infection or vaccination.
Baseline Characteristics of the Included 48 210 Employees of Cleveland Clinic in Ohio, and Features of Those who Did and Did not Receive the 2023–2024 Formulation COVID-19 Vaccine by the end of the Study
| Characteristics . | All Subjects (n = 48 210) . | Vaccinateda by the End of the Study (n = 7978) . | Not Vaccinateda by the End of the Study (n = 40 232) . | P . |
|---|---|---|---|---|
| Age in y, mean (SD) | 42.0 (13.4) | 47.6 (13.9) | 40.9 (13.0) | <.001 |
| Sex | <.001 | |||
| Female | 35 959 (74.6) | 5421 (67.9) | 30 538 (75.9) | |
| Male | 12 251 (25.4) | 2557 (32.1) | 9694 (24.1) | |
| Location | <.001 | |||
| Cleveland Clinic Main | 19 935 (41.4) | 4476 (56.1) | 15 459 (38.4) | |
| Cleveland area regional hospitals | 12 289 (25.5) | 1450 (18.2) | 10 839 (26.9) | |
| Ambulatory centers | 8922 (18.5) | 1198 (15.0) | 7724 (19.2) | |
| Cleveland Clinic Akron | 4075 (8.5) | 348 (4.4) | 3727 (9.3) | |
| Administrative centers | 1779 (3.7) | 377 (4.7) | 1402 (3.5) | |
| Cleveland Clinic Medina | 1210 (2.5) | 129 (1.6) | 1081 (2.7) | |
| Hire cohort | <.001 | |||
| Prepandemic | 28 030 (58.1) | 5404 (67.7) | 22 626 (56.2) | |
| Pandemic | 20 180 (41.9) | 2574 (32.3) | 17 606 (43.8) | |
| Pandemic phase during which most recent infection occurred | <.001 | |||
| Not previously known to be infected | 26 494 (55.0) | 4526 (56.7) | 21 968 (54.6) | |
| Pre-Omicron | 5055 (10.5) | 472 (5.9) | 4583 (11.4) | |
| Omicron pre-XBB | 13 499 (28.0) | 2360 (29.6) | 11 139 (27.7) | |
| Omicron XBB or later | 3162 (6.6) | 620 (7.8) | 2542 (6.3) | |
| Days since most recent infection, mean (SD) | 544 (284) | 478 (260) | 557 (286) | <.001 |
| Prior vaccination history | <.001 | |||
| Monovalent and bivalent vaccines | 12 264 (25.4) | 5876 (73.7) | 6388 (15.9) | |
| Bivalent vaccine only | 379 (<1) | 111 (1.4) | 268 (<1) | |
| Monovalent vaccine only | 28 192 (58.5) | 1722 (21.6) | 26 470 (65.8) | |
| Non-mRNA vaccine only | 913 (1.9) | 23 (<1) | 890 (2.2) | |
| No vaccine | 6462 (13.4) | 246 (3.1) | 6216 (15.5) | |
| Number of prior vaccine doses | <.001 | |||
| 0 | 6462 (13.4) | 246 (3.1) | 6216 (15.5) | |
| 1 | 1904 (3.9) | 134 (1.7) | 1770 (4.4) | |
| 2 | 13 381 (27.8) | 303 (3.8) | 13 078 (32.5) | |
| 3 | 14 106 (29.3) | 1287 (16.1) | 12 819 (31.9) | |
| >3 | 12 357 (25.6) | 6008 (75.3) | 6349 (15.8) | |
| Days since most recent vaccine, mean (SD) | 597 (232) | 377 (197) | 648 (209) | <.001 |
| Days since proximate SARS-CoV-2 exposureb, mean (SD) | 513 (239) | 339 (188) | 551 (232) | <.001 |
| Characteristics . | All Subjects (n = 48 210) . | Vaccinateda by the End of the Study (n = 7978) . | Not Vaccinateda by the End of the Study (n = 40 232) . | P . |
|---|---|---|---|---|
| Age in y, mean (SD) | 42.0 (13.4) | 47.6 (13.9) | 40.9 (13.0) | <.001 |
| Sex | <.001 | |||
| Female | 35 959 (74.6) | 5421 (67.9) | 30 538 (75.9) | |
| Male | 12 251 (25.4) | 2557 (32.1) | 9694 (24.1) | |
| Location | <.001 | |||
| Cleveland Clinic Main | 19 935 (41.4) | 4476 (56.1) | 15 459 (38.4) | |
| Cleveland area regional hospitals | 12 289 (25.5) | 1450 (18.2) | 10 839 (26.9) | |
| Ambulatory centers | 8922 (18.5) | 1198 (15.0) | 7724 (19.2) | |
| Cleveland Clinic Akron | 4075 (8.5) | 348 (4.4) | 3727 (9.3) | |
| Administrative centers | 1779 (3.7) | 377 (4.7) | 1402 (3.5) | |
| Cleveland Clinic Medina | 1210 (2.5) | 129 (1.6) | 1081 (2.7) | |
| Hire cohort | <.001 | |||
| Prepandemic | 28 030 (58.1) | 5404 (67.7) | 22 626 (56.2) | |
| Pandemic | 20 180 (41.9) | 2574 (32.3) | 17 606 (43.8) | |
| Pandemic phase during which most recent infection occurred | <.001 | |||
| Not previously known to be infected | 26 494 (55.0) | 4526 (56.7) | 21 968 (54.6) | |
| Pre-Omicron | 5055 (10.5) | 472 (5.9) | 4583 (11.4) | |
| Omicron pre-XBB | 13 499 (28.0) | 2360 (29.6) | 11 139 (27.7) | |
| Omicron XBB or later | 3162 (6.6) | 620 (7.8) | 2542 (6.3) | |
| Days since most recent infection, mean (SD) | 544 (284) | 478 (260) | 557 (286) | <.001 |
| Prior vaccination history | <.001 | |||
| Monovalent and bivalent vaccines | 12 264 (25.4) | 5876 (73.7) | 6388 (15.9) | |
| Bivalent vaccine only | 379 (<1) | 111 (1.4) | 268 (<1) | |
| Monovalent vaccine only | 28 192 (58.5) | 1722 (21.6) | 26 470 (65.8) | |
| Non-mRNA vaccine only | 913 (1.9) | 23 (<1) | 890 (2.2) | |
| No vaccine | 6462 (13.4) | 246 (3.1) | 6216 (15.5) | |
| Number of prior vaccine doses | <.001 | |||
| 0 | 6462 (13.4) | 246 (3.1) | 6216 (15.5) | |
| 1 | 1904 (3.9) | 134 (1.7) | 1770 (4.4) | |
| 2 | 13 381 (27.8) | 303 (3.8) | 13 078 (32.5) | |
| 3 | 14 106 (29.3) | 1287 (16.1) | 12 819 (31.9) | |
| >3 | 12 357 (25.6) | 6008 (75.3) | 6349 (15.8) | |
| Days since most recent vaccine, mean (SD) | 597 (232) | 377 (197) | 648 (209) | <.001 |
| Days since proximate SARS-CoV-2 exposureb, mean (SD) | 513 (239) | 339 (188) | 551 (232) | <.001 |
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: COVID-19, coronavirus disease 2019; mRNA, messenger RNA; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation.
aWith the 2023–2024 formulation vaccine.
bBy infection or vaccination.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
